|
Multi-Year Agreement Enables Global CRO to Offer Phase
Forward's InForm? EDC Solution to PharmaNet Customers Worldwide
WALTHAM, Mass.(BUSINESS WIRE)
Phase Forward (NASDAQ: PFWD), a leading provider of data management
solutions for clinical trials and drug safety, today announced a
multi-year agreement with PharmaNet Development Group, Inc., a global
drug development services company, that enables PharmaNet to offer Phase
Forward's InForm? electronic data capture (EDC) solution to
PharmaNet customers worldwide. PharmaNet provides a comprehensive range
of services to the pharmaceutical, biotechnology, generic drug and
medical device industries that includes clinical trial data management.
We chose to team with Phase Forward on the basis of our successful
collaboration on behalf of several pharmaceutical companies,? said
Thomas Newman, M.D., President, PharmaNet Late Stage Development. That
experience indicated the complementary nature of Phase Forward's
established leadership in EDC technology solutions and our expertise in
providing clinical trial services to a broad range of industries. We
look forward to extending to other customers the success our work
together has already achieved.?
Customers are turning to PharmaNet for its proven expertise in
providing the critical services infrastructure required to optimize the
clinical trial process,? said Steve Powell, senior vice president, Phase
Forward. Our InForm EDC solution is a perfect addition to PharmaNet's
expertise and we look forward to building on and expanding our work
together.?
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services
company, provides a comprehensive range of services to the
pharmaceutical, biotechnology, generic drug and medical device
industries. The Company offers early and late stage consulting, Phase I
clinical studies and bioanalytical analyses, and Phase II, III and IV
clinical development programs. With approximately 2,300 employees and 40
facilities throughout the world, PharmaNet is a recognized leader in
outsourced clinical development. For more information, please visit our
website at www.pharmanet.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. Phase Forward's products
and services have been utilized in over 10,000 clinical trials involving
more than 1,000,000 clinical trial study participants at over 300
organizations and regulatory agencies worldwide including: AstraZeneca,
Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S.
Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research
Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International,
Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare
Products Regulatory Agency. Additional information about Phase Forward
is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based on
historical information are forward-looking statements which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things, the
performance and features of Phase Forward's products and services,
demand for Phase Forward's products and services, future business and
operations plans of a Phase Forward customer, and the ability of Phase
Forward's customers to realize benefits from the use of Phase Forward's
products and services. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond Phase Forward's control, which could cause
actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties
include, among other things, the ability of Phase Forward's customers to
realize benefits from the use of its products and services, the
possibility that customers needs or plans may change over time, the
possibility that the level of demand for Phase Forward's products and
services may vary, regulatory changes and competition. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Phase Forward undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise. For additional
disclosure regarding these and other risks faced by Phase Forward, see
the disclosure contained in Phase Forward's public filings with the
Securities and Exchange Commission including, without limitation, its
most recent Annual Report on Form 10-K.
Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN
PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com
Source: Phase Forward
|
